Forte Biosciences shares collapse after lead bacteria drug flops key eczema study
With a unique strategy to take on eczema with a combination of “therapeutic” bacteria strains, Forte Biosciences has now folded like a house of cards after its lead drug flopped a key study.
Forte’s atopic dermatitis candidate FB-401, a combination of three strains of commensal gram-negative bacteria, failed its primary endpoint reducing the severity of symptoms by 50% or more against placebo, the company said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.